Memorial Sloan Kettering Cancer Center: Carcinoma, Ovarian Epithelial trials

The registry lists 27 Carcinoma, Ovarian Epithelial studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 2 are open to participants now and 4 have results posted.

Early Phase 1 1Phase 1 5Phase 2 8No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Isoquercetin in People With Ovarian CancerRecruitingNCT07303894Phase 2
• A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)RecruitingNCT05429970Not applicable
• TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian CancerCompletedNCT02764333Phase 2Results posted
• Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell ProliferationCompletedNCT02477202Not applicableResults posted
• Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)CompletedNCT00562640Phase 1Results posted
• Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second RemissionTerminatedNCT00522301Phase 2Results posted
• A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of ChemotherapyActive, not recruitingNCT06240598Phase 2
• Continued Access to RXDX-105CompletedNCT03784378Phase 1
• Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative StudyCompletedNCT02928549
• A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian CancerCompletedNCT02737787Phase 1
• Yoga Practice for Breast or Ovarian Cancer PatientsCompletedNCT02305498Not applicable
• Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And GenomicsCompletedNCT02144311Not applicable
• Structural and Functional Imaging and Cognitive Functions in Ovarian CancerCompletedNCT01591772
• Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian CancerCompletedNCT01471483
• Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian CancerCompletedNCT01442051Not applicable
• Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot StudyCompletedNCT00946140
• Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer RiskCompletedNCT00735150
• Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.CompletedNCT00620243Early Phase 1
• Sexual Functioning After Primary Treatment of Ovarian CancerTerminatedNCT00596544
• Women Surviving Ovarian CancerCompletedNCT00596349
• A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian CancerCompletedNCT00587093Not applicable
• Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00028912Phase 1
• TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00022347Phase 2
• Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00021034Phase 1
• Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian CancerCompletedNCT00016224Phase 2
• Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00003345Phase 2
• Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian CancerCompletedNCT00002928Phase 2